Shayna Sarosiek
Overview
Explore the profile of Shayna Sarosiek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
562
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bibas M, Sarosiek S, Castillo J
Mediterr J Hematol Infect Dis
. 2025 Mar;
17(1):e2025015.
PMID: 40084099
Key Points: WM has no cure, but therapies can improve survival. Treatment for WM/LPL patients should be initiated when they exhibit symptoms, and the IgM level should not determine WM...
2.
Paludo J, Abeykoon J, Perera N, Sarosiek S, Gustine J, Ramirez-Gamero A, et al.
Am J Hematol
. 2025 Mar;
PMID: 40062689
As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However,...
3.
Sarosiek S, Ramirez-Gamero A, Flynn C, Treon S, Castillo J
Br J Haematol
. 2025 Feb;
PMID: 39967276
Infiltration of the central nervous system by malignant lymphoplasmacytic cells is a rare complication of Waldenström macroglobulinaemia (WM) and is referred to as Bing-Neel syndrome (BNS). Traditionally, the treatment of...
4.
Sarosiek S, Doughty C, Castillo J
Curr Hematol Malig Rep
. 2024 Dec;
20(1):2.
PMID: 39680359
Purpose Of Review: Peripheral neuropathy (PN) is more commonly seen in individuals with monoclonal gammopathies, especially in patients with an IgM monoclonal gammopathy or Waldenström macroglobulinemia. Recent Findings: There are...
5.
Bibas M, Sarosiek S, Castillo J
Mediterr J Hematol Infect Dis
. 2024 Jul;
16(1):e2024061.
PMID: 38984103
Waldenström macroglobulinemia (WM) is an infrequent variant of lymphoma, classified as a B-cell malignancy identified by the presence of IgM paraprotein, infiltration of clonal, small lymphoplasmacytic B cells in the...
6.
Zanwar S, Le-Rademacher J, Durot E, DSa S, Abeykoon J, Mondello P, et al.
J Clin Oncol
. 2024 May;
42(21):2527-2536.
PMID: 38788183
Purpose: Patients with Waldenström macroglobulinemia (WM) have disparate outcomes. Newer therapies have emerged since the development of International Prognostic Scoring System, and mutation is now frequently assessed at diagnosis, warranting...
7.
Sarosiek S, Castillo J
J Natl Compr Canc Netw
. 2024 May;
22(4).
PMID: 38754469
Bruton tyrosine kinase (BTK) inhibitors have become a standard of care in the treatment of patients with Waldenström macroglobulinemia (WM) and are the only medications approved by the FDA to...
8.
Treon S, Sarosiek S, Castillo J
Blood
. 2024 Jan;
143(17):1702-1712.
PMID: 38211337
Mutations in MYD88 (95%-97%) and CXCR4 (30%-40%) are common in Waldenström macroglobulinemia (WM). TP53 is altered in 20% to 30% of patients with WM, particularly those previously treated. Mutated MYD88...
9.
Sarosiek S, Castillo J
Drugs
. 2023 Dec;
84(1):17-25.
PMID: 38055179
With the worldwide approval of the oral covalent Bruton tyrosine kinase (BTK) inhibitors ibrutinib and zanubrutinib for treating patients with Waldenström macroglobulinemia (WM), targeted agents have certainly taken center stage...
10.
Castillo J, Branagan A, Sermer D, Flynn C, Meid K, Little M, et al.
Blood
. 2023 Nov;
143(7):582-591.
PMID: 37971194
Concurrent Bruton tyrosine kinase and BCL2 inhibition has not yet been investigated in Waldenström macroglobulinemia (WM). We performed an investigator-initiated trial of ibrutinib and venetoclax in symptomatic treatment-naïve patients with...